Abstract
Chronic myeloid leukemia (CML) is a slow-growing type of cancer that originates in the blood-forming cells of the bone marrow and is caused by a chromosomal mutation that is thought to occur spontaneously. CML could potentially lead to the development of myeloid sarcoma (MS), which is a rare neoplasm composed of immature myeloid cells that could evolve into a tumor mass at any anatomical site other than the bone marrow. MS can develop spontaneously or as a result of another form of myeloid neoplasm. Most instances of CML precede blast phase (BP) within two to three years after the first diagnosis of CML chronic phase (CP) at the age of pre-tyrosine kinase inhibitor (TKI) treatment. MS developing in CML patients during the era of TKI treatment is infrequently mentioned in the literature, primarily in single-case studies. As a result, the prognostic influence of MS in CML patients has not been well investigated. In the age of TKI treatment, it is uncertain whether MS and medullary BP have comparable clinical and prognostic relevance. The precise diagnosis of MS is critical for effective treatment, which is frequently delayed due to a high risk of misdiagnosis.This review focuses on the relationship between the development of MS from CML, and it culminates with recommendations for future hematology practice. A literature search was conducted in multiple databases, and the studies were appraised based on the inclusion and exclusion criteria.Finally, studies to date have shown that the existence of CML and its possible progression to MS in individuals map out the numerous implications this disease has in hematology practice. Though occurrences are uncommon in general, the prognosis for patients is bleak, necessitating the exploration and implementation of diagnostic and therapy advancements. Because there is limited evidence in the literature on its existence in the medullary chronic phase and outcomes in the era of TKI, it must be carefully investigated because it might be the first symptom of progressive illness prior to hematological progression.
Highlights
BackgroundDiseases of the blood can have significant acute and chronic impacts on the patient's quality of life
This review focuses on the relationship between the development of myeloid sarcoma (MS) from chronic myeloid leukemia (CML), and it culminates with recommendations for future hematology practice
One common form of leukemia impacting adults in contemporary society includes the onset of acute myeloid leukemia (AML), which accounts for an estimated 80% of cases of leukemia [2]
Summary
BackgroundDiseases of the blood can have significant acute and chronic impacts on the patient's quality of life. The presence of a chronic form of myeloid leukemia, known as chronic myeloid leukemia (CML), can ensue, impacting the functioning of white blood cells in afflicted patients. The word "chloroma" comes from the Greek word "chloros" meaning "the color green" [5] It shows the tumor's greenish tint caused by the presence and oxidation of the enzyme myeloperoxidase [6]. These tumors can develop independently or in conjunction with other myeloid illnesses such as AML or CML, myeloproliferative or myelodysplastic syndromes [6]. The presence of myeloid sarcoma results from a developing tumor created by hematopoietic neoplasm [7] It can originate anywhere, resulting in a wide range of clinical manifestations [8]. The diagnosis is complex and requires a high index of suspicion, as well as radiography, histology, immunophenotyping, and molecular analysis, which are required for risk stratification and treatment planning [7]
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
